Vanguard Group
AQST icon

Vanguard Group’s Aquestive Therapeutics AQST Stock Holding History

Vanguard Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$38.1M Buy
5,892,334
+230,202
+4% +$1.43M ﹤0.01% 2312
2025
Q3 		$31.7M Buy
5,662,132
+1,333,627
+31% +$5.77M ﹤0.01% 2393
2025
Q2 		$14.3M Buy
4,328,505
+254,947
+6% +$731K ﹤0.01% 2719
2025
Q1 		$11.8M Sell
4,073,558
-273,196
-6% -$827K ﹤0.01% 2753
2024
Q4 		$15.5M Buy
4,346,754
+82,958
+2% +$383K ﹤0.01% 2717
2024
Q3 		$21.2M Buy
4,263,796
+36,124
+0.9% +$141K ﹤0.01% 2568
2024
Q2 		$11M Buy
4,227,672
+985,101
+30% +$3.29M ﹤0.01% 2858
2024
Q1 		$13.8M Buy
3,242,571
+1,353,518
+72% +$4.51M ﹤0.01% 2783
2023
Q4 		$3.82M Buy
1,889,053
+190,401
+11% +$336K ﹤0.01% 3390
2023
Q3 		$2.6M Buy
1,698,652
+138,984
+9% +$239K ﹤0.01% 3499
2023
Q2 		$2.57M Buy
1,559,668
+249,082
+19% +$451K ﹤0.01% 3582
2023
Q1 		$1.49M Buy
1,310,586
+65,854
+5% +$57.1K ﹤0.01% 3784
2022
Q4 		$1.12M Buy
1,244,732
+63,192
+5% +$59.3K ﹤0.01% 3868
2022
Q3 		$1.38M Sell
1,181,540
-100,966
-8% -$114K ﹤0.01% 3889
2022
Q2 		$820K Hold
1,282,506
– – ﹤0.01% 4150
2022
Q1 		$3.35M Buy
1,282,506
+40,317
+3% +$118K ﹤0.01% 3724
2021
Q4 		$4.83M Buy
1,242,189
+187,885
+18% +$943K ﹤0.01% 3630
2021
Q3 		$4.6M Buy
1,054,304
+8,226
+0.8% +$32.3K ﹤0.01% 3717
2021
Q2 		$4.15M Buy
1,046,078
+189,652
+22% +$757K ﹤0.01% 3685
2021
Q1 		$4.45M Sell
856,426
-37,969
-4% -$202K ﹤0.01% 3588
2020
Q4 		$4.79M Buy
894,395
+33,485
+4% +$201K ﹤0.01% 3380
2020
Q3 		$4.18M Buy
860,910
+121,138
+16% +$792K ﹤0.01% 3238
2020
Q2 		$3.6M Buy
739,772
+112,964
+18% +$520K ﹤0.01% 3241
2020
Q1 		$1.37M Buy
626,808
+34,400
+6% +$131K ﹤0.01% 3412
2019
Q4 		$3.45M Buy
592,408
+312,996
+112% +$1.63M ﹤0.01% 3290
2019
Q3 		$889K Sell
279,412
-32,719
-10% -$123K ﹤0.01% 3682
2019
Q2 		$1.31M Sell
312,131
-81,513
-21% -$417K ﹤0.01% 3590
2019
Q1 		$2.72M Buy
393,644
+54,196
+16% +$380K ﹤0.01% 3354
2018
Q4 		$2.14M Sell
339,448
-120,584
-26% -$1.52M ﹤0.01% 3354
2018
Q3 		$8.05M Buy
+460,032
New +$7.58M ﹤0.01% 3028

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group's AQST Position: Q4 2025 in Review

Vanguard Group increased its Aquestive Therapeutics (AQST) stake by 4.1% in Q4 2025, buying an estimated $1.43M and bringing the position to 5,892,334 shares worth $38.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2312.

Vanguard Group first reported a position in AQST in Q3 2018 and has held it in 30 quarters since. 176 funds tracked by Wall St. Rank hold AQST as of Q4 2025.

  • Vanguard Group held 5,892,334 shares of Aquestive Therapeutics worth $38.1M as of Q4 2025.
  • Vanguard Group bought 230,202 Aquestive Therapeutics shares in Q4 2025, an estimated $1.43M.
  • Aquestive Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2312 holding.
  • Vanguard Group first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 30 quarters since.
  • 176 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.